EPISODE · Nov 11, 2024 · 18 MIN
Should the FDA be requiring a Risk Evaluation and Mitigation Strategy for mifepristone? - Ep 147
from ACCP JOURNALS · host ACCP JOURNALS
Explore the basis for and controversy surrounding the US Food and Drug Administration requiring a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. Full text of the manuscript is available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.2034.
Embed this episode
NOW PLAYING
Should the FDA be requiring a Risk Evaluation and Mitigation Strategy for mifepristone? - Ep 147
0:00
18:01
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Neurology® Podcast
American Academy of Neurology
The Neurology Podcast provides practical information for neurologists and clinicians to practice the best possible medicine for patients. Examining methods and findings in peer-reviewed journals, the show provides insights that impact clinical practice and patient care. From the journal Neurology and the American Academy of Neurology, providing education and expert analysis since 2007.
Dermasphere - The Dermatology Podcast
Luke Johnson
For dermatology practitioners, Dermasphere covers the most important updates from the latest articles and research in the field. Maybe you don’t have time to read the journals—but we hope you have time to listen to a podcast about them!
Frequently Asked Questions
How long is this episode of ACCP JOURNALS?
This episode is 18 minutes long.
When was this ACCP JOURNALS episode published?
This episode was published on November 11, 2024.
Can I download this ACCP JOURNALS episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!